' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 31 Researches
7.1
USERS' SCORE
Good
Based on 5 Reviews
8.7
Supplement Facts
Serving Size: 1 softgel
Amount Per Serving
%DV
Calories
9
Calories from Fat
7
Total Fat
1 g
1%¹
Saturated Fat
0 g
0%¹
Unsaturated Fat
0.5 g
Trans Fat
0 g
Total Omega-3 Fatty Acids
640 mg
+
DHA (Docosahexanoic Acid)
480 mg
EPA (Eicosapentaenoic Acid)
104 mg
Other Omega-3s
56 mg
Top Medical Research Studies
8
DHA shows potential for depression
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Direct assessment of DHA's effects
We conducted a study to find out whether docosahexaenoic acid (DHA), a type of omega-3 fatty acid, could effectively help those dealing with major depressive disorder (MDD). Over the course of 12 weeks, 60 participants were involved in a double-blind, placebo-controlled trial. They were divided into two groups: one received 3.2 grams of DHA daily, while the other group was given an equivalent amount of soybean oil as a placebo.
Throughout the study, we measured depression levels using the Hamilton Rating Scale for Depression (HRSD). Our results were intriguing—those taking the DHA showed significant improvements in their depression scores compared to the placebo group by weeks 4, 6, 8, and 12. While we noted that 26.7% of participants receiving DHA achieved remission by week 12, this was not statistically significant in comparison to the placebo group.
Overall, our findings support the idea that DHA may serve as a promising alternative treatment for individuals suffering from MDD. Although the results are encouraging, we recognize the need for further research to confirm these benefits conclusively.
Throughout the study, we measured depression levels using the Hamilton Rating Scale for Depression (HRSD). Our results were intriguing—those taking the DHA showed significant improvements in their depression scores compared to the placebo group by weeks 4, 6, 8, and 12. While we noted that 26.7% of participants receiving DHA achieved remission by week 12, this was not statistically significant in comparison to the placebo group.
Overall, our findings support the idea that DHA may serve as a promising alternative treatment for individuals suffering from MDD. Although the results are encouraging, we recognize the need for further research to confirm these benefits conclusively.
Read More
8
Eicosapentaenoic acid may reduce depression
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Direct focus on EPA's efficacy
We conducted a study to explore the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, in treating major depressive disorder (MDD). Over the course of 12 weeks, 60 participants suffering from MDD were divided into two groups: one received 3.2 grams of EPA daily, while the other group was given a placebo, which was soybean oil.
Throughout the study, we assessed the severity of depression using the Hamilton Rating Scale for Depression (HRSD). What we found was promising. The group taking EPA experienced significantly lower HRSD scores at various checkpoints—specifically at weeks 4, 6, 8, and 12—indicating a reduction in depressive symptoms. Although the rates of remission and response were higher in the EPA group compared to the placebo group, these findings did not achieve statistical significance.
Overall, while EPA shows potential as a treatment for depression, further research is needed to solidify its role. Our findings suggest that it may be an alternative option for MDD patients seeking additional treatment pathways.
Throughout the study, we assessed the severity of depression using the Hamilton Rating Scale for Depression (HRSD). What we found was promising. The group taking EPA experienced significantly lower HRSD scores at various checkpoints—specifically at weeks 4, 6, 8, and 12—indicating a reduction in depressive symptoms. Although the rates of remission and response were higher in the EPA group compared to the placebo group, these findings did not achieve statistical significance.
Overall, while EPA shows potential as a treatment for depression, further research is needed to solidify its role. Our findings suggest that it may be an alternative option for MDD patients seeking additional treatment pathways.
Read More
5
Potential benefits for depression prevention
The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial.
Focused on eicosapentaenoic acid
We conducted a study to explore whether eicosapentaenoic acid (a type of omega-3 fatty acid) can help prevent depression recurrence in older adults who have previously experienced late-life depression. Our research involved a rigorous 52-week double-blind, placebo-controlled trial with 39 patients who were currently stable and free from depression symptoms.
The participants were randomly assigned to either receive daily doses of eicosapentaenoic acid alongside docosahexaenoic acid or a placebo for the duration of the trial. We wanted to see if this supplementation could not only protect against future depressive episodes but also impact depressive and anxiety symptoms, as well as some inflammatory markers associated with depression.
Interestingly, our findings revealed that eicosapentaenoic acid did indeed show a protective effect against the recurrence of depression, with a significant hazard ratio suggesting that those taking the supplement were less likely to relapse compared to the placebo group. However, we didn't observe any notable improvements in current depressive or anxiety symptoms, nor in the inflammatory markers between the two groups.
While the results are promising regarding the prevention of depression recurrence, it's essential to keep in mind the modest size of our sample when interpreting these findings.
The participants were randomly assigned to either receive daily doses of eicosapentaenoic acid alongside docosahexaenoic acid or a placebo for the duration of the trial. We wanted to see if this supplementation could not only protect against future depressive episodes but also impact depressive and anxiety symptoms, as well as some inflammatory markers associated with depression.
Interestingly, our findings revealed that eicosapentaenoic acid did indeed show a protective effect against the recurrence of depression, with a significant hazard ratio suggesting that those taking the supplement were less likely to relapse compared to the placebo group. However, we didn't observe any notable improvements in current depressive or anxiety symptoms, nor in the inflammatory markers between the two groups.
While the results are promising regarding the prevention of depression recurrence, it's essential to keep in mind the modest size of our sample when interpreting these findings.
Read More
Most Useful Reviews
9.5
Reduced depression
I’ve been taking this for three months and feel it helps with my depression.
Read More
9.5
Improved mood
I took this for over a month before giving birth and continued afterwards. It’s a brand I trust, and the quality is unquestionable. I believe this, alongside the benefits of omega, contributes to my great mood and overall well-being, helping me avoid depression.
Read More
8.8
Effective supplement
These vitamins are excellent! They have genuinely helped me with my depression and improved my skin. I highly recommend them.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 31 Researches
7.1
9
DHA beneficial for depression
Plasma Polyunsaturated Fatty Acid Levels and Mental Health in Middle-Aged and Elderly Adults.
Moderate relevance to DHA effects
We explored the intriguing relationship between docosahexaenoic acid (DHA), a type of omega-3 polyunsaturated fatty acid, and its potential effects on depression among middle-aged and elderly adults. Our research pulled from a substantial sample size of over 102,000 residents from the UK Biobank, enabling us to thoroughly investigate how varying levels of PUFAs, particularly DHA, are associated with depressive and anxiety disorders.
The findings revealed that higher plasma levels of DHA were linked to a lower risk of developing depressive disorders compared to those with lower levels. Specifically, we observed a hazard ratio of 0.80 for individuals with the highest DHA levels, indicating a significant protective effect. This trend extended to anxiety disorders as well, suggesting that increasing our intake of omega-3 PUFAs might be a reachable goal for enhancing mental health.
Additionally, we noted that higher levels of DHA were also related to a decrease in adverse psychological symptoms. Encompassing the impact on brain health, we incorporated neuroimaging data from nearly 8,800 participants to investigate white matter microstructures, further supporting the link between omega-3 PUFAs like DHA and overall mental well-being.
The evidence we gathered underscores the importance of considering omega-3 PUFAs, particularly DHA, as a promising nutritional approach for helping to prevent and manage depression in older adults.
The findings revealed that higher plasma levels of DHA were linked to a lower risk of developing depressive disorders compared to those with lower levels. Specifically, we observed a hazard ratio of 0.80 for individuals with the highest DHA levels, indicating a significant protective effect. This trend extended to anxiety disorders as well, suggesting that increasing our intake of omega-3 PUFAs might be a reachable goal for enhancing mental health.
Additionally, we noted that higher levels of DHA were also related to a decrease in adverse psychological symptoms. Encompassing the impact on brain health, we incorporated neuroimaging data from nearly 8,800 participants to investigate white matter microstructures, further supporting the link between omega-3 PUFAs like DHA and overall mental well-being.
The evidence we gathered underscores the importance of considering omega-3 PUFAs, particularly DHA, as a promising nutritional approach for helping to prevent and manage depression in older adults.
Read More
9
Omega-3 helps juvenile depression
Omega-3 alleviates behavioral and molecular changes in a mouse model of stress-induced juvenile depression.
Validates omega-3's effectiveness in depression
We used a unique model to explore how docosahexaenoic acid, an omega-3 fatty acid, may help alleviate symptoms of depression in young mice. By exposing juvenile mice to alternating ultrasound stress frequencies known to induce depressive-like behaviors, we aimed to mimic conditions of juvenile depression.
Throughout the study, these mice received either a supplement containing both DHA and eicosapentaenoic acid (EPA) or a placebo. The results were quite promising! Mice treated with the omega-3 supplement showed significantly fewer signs of depression and anxiety compared to those that received the placebo. This included a noticeable improvement in behaviors related to pleasure and reduced anxiety.
Additionally, the omega-3 treatment seemed to have a positive effect on hormone levels and inflammatory markers in the brain, indicating that the anti-inflammatory properties of DHA could be part of its effectiveness. Overall, our findings suggest that omega-3 fatty acids might hold potential as a therapeutic option for addressing juvenile depression.
Throughout the study, these mice received either a supplement containing both DHA and eicosapentaenoic acid (EPA) or a placebo. The results were quite promising! Mice treated with the omega-3 supplement showed significantly fewer signs of depression and anxiety compared to those that received the placebo. This included a noticeable improvement in behaviors related to pleasure and reduced anxiety.
Additionally, the omega-3 treatment seemed to have a positive effect on hormone levels and inflammatory markers in the brain, indicating that the anti-inflammatory properties of DHA could be part of its effectiveness. Overall, our findings suggest that omega-3 fatty acids might hold potential as a therapeutic option for addressing juvenile depression.
Read More
9
DHA alleviates epilepsy-related depression
DHA and EPA Alleviate Epileptic Depression in PTZ-Treated Young Mice Model by Inhibiting Neuroinflammation through Regulating Microglial M2 Polarization and Improving Mitochondrial Metabolism.
Focus on DHA's isolated effects
We explored the impact of docosahexaenoic acid (DHA) on depressive symptoms associated with epilepsy in a young mouse model. Through our investigation, we fed mice a diet enriched with DHA and administered pentylenetetrazole (PTZ) to induce epilepsy. Notably, our findings indicated that both DHA and eicosapentaenoic acid (EPA) significantly reduced depressive symptoms in this model, with EPA showing even greater effectiveness.
Analyzing the underlying mechanisms revealed that DHA and EPA helped repair neuronal damage and improve myelin structure in the hippocampus—the brain region vital for mood regulation. Furthermore, they tackled neuroinflammation by encouraging the polarizing of microglial cells toward a protective state and suppressing harmful inflammatory responses.
Additionally, we observed that both fatty acids decreased oxidative stress and improved mitochondrial function, which are crucial aspects of brain health. These results suggest that integrating DHA (and EPA) into dietary interventions could offer a promising strategy to alleviate depression in children with epilepsy, providing a potential pathway to enhance their quality of life.
Analyzing the underlying mechanisms revealed that DHA and EPA helped repair neuronal damage and improve myelin structure in the hippocampus—the brain region vital for mood regulation. Furthermore, they tackled neuroinflammation by encouraging the polarizing of microglial cells toward a protective state and suppressing harmful inflammatory responses.
Additionally, we observed that both fatty acids decreased oxidative stress and improved mitochondrial function, which are crucial aspects of brain health. These results suggest that integrating DHA (and EPA) into dietary interventions could offer a promising strategy to alleviate depression in children with epilepsy, providing a potential pathway to enhance their quality of life.
Read More
9
EPA alleviates depressive behavior
DHA and EPA alleviate depressive-like behaviors in chronic sleep-deprived mice: Involvement of iron metabolism, oligodendrocyte-lipids peroxidation and the LCN2-NLRP3 signaling axis.
High relevance to depression treatment
We investigated how eicosapentaenoic acid (EPA) impacts depressive-like behaviors in mice that were subject to chronic sleep deprivation. Our findings indicated that EPA is more effective than docosahexaenoic acid (DHA) in alleviating signs of depression, as evidenced by changes in preferences and behaviors observed in these mice.
Both EPA and DHA were shown to reduce myelin damage and support the health of oligodendrocytes, but EPA led to more significant improvements. We noted higher levels of essential proteins related to myelin repair alongside reduced lipid peroxidation in the presence of EPA.
Notably, both compounds inhibited inflammation pathways associated with depression. However, EPA markedly outperformed DHA in curbing microglial activation and correcting imbalances in immune response. Overall, our research supports the understanding of EPA as a particularly promising option in the fight against depression.
Both EPA and DHA were shown to reduce myelin damage and support the health of oligodendrocytes, but EPA led to more significant improvements. We noted higher levels of essential proteins related to myelin repair alongside reduced lipid peroxidation in the presence of EPA.
Notably, both compounds inhibited inflammation pathways associated with depression. However, EPA markedly outperformed DHA in curbing microglial activation and correcting imbalances in immune response. Overall, our research supports the understanding of EPA as a particularly promising option in the fight against depression.
Read More
9
DPA enhances depression treatment efficacy
Exosomes Derived from DPA-treated UCMSCs Attenuated Depression-like Behaviors and Neuroinflammation in a Model of Depression Induced by Chronic Stress.
Combines treatments complicate results
We explored the therapeutic benefits of eicosapentaenoic acid (DPA) in treating depression, particularly in relation to exosomes derived from human umbilical cord mesenchymal stem cells. Chronic unpredictable mild stress (CUMS) was used to induce depression-like behaviors in the study, which highlighted the role of neuroinflammation and neurotransmitter deficiencies in this condition.
Through our analysis, we observed that DPA not only improved the effectiveness of exosomes but also significantly alleviated symptoms of depression. The therapy showed a remarkable ability to suppress the harmful activation of specific immune cells in the brain, known as M1 microglia, which are often linked to inflammation. Additionally, DPA helped restore levels of important neurotransmitters, including serotonin and dopamine.
Furthermore, in laboratory tests, the exosomes treated with DPA demonstrated better protective effects against cell death and inflammation-induced damage. Mechanistically, this positive outcome was attributed to DPA’s ability to enhance the expression of a particular microRNA that plays a role in reducing inflammation pathways.
Overall, our findings suggest that DPA treatment combined with exosomes not only addresses neuroinflammation but also promotes overall brain health. This makes it a promising avenue for developing more effective depression treatments.
Through our analysis, we observed that DPA not only improved the effectiveness of exosomes but also significantly alleviated symptoms of depression. The therapy showed a remarkable ability to suppress the harmful activation of specific immune cells in the brain, known as M1 microglia, which are often linked to inflammation. Additionally, DPA helped restore levels of important neurotransmitters, including serotonin and dopamine.
Furthermore, in laboratory tests, the exosomes treated with DPA demonstrated better protective effects against cell death and inflammation-induced damage. Mechanistically, this positive outcome was attributed to DPA’s ability to enhance the expression of a particular microRNA that plays a role in reducing inflammation pathways.
Overall, our findings suggest that DPA treatment combined with exosomes not only addresses neuroinflammation but also promotes overall brain health. This makes it a promising avenue for developing more effective depression treatments.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.7
9.5
Reduced depression
I’ve been taking this for three months and feel it helps with my depression.
9.5
Improved mood
I took this for over a month before giving birth and continued afterwards. It’s a brand I trust, and the quality is unquestionable. I believe this, alongside the benefits of omega, contributes to my great mood and overall well-being, helping me avoid depression.
8.8
Effective supplement
These vitamins are excellent! They have genuinely helped me with my depression and improved my skin. I highly recommend them.
8.8
Supports mental health
My obstetrician recommended omega-3 for both the baby and me, particularly to lower the risk of postpartum depression. I don’t like fish, so I opted for this supplement, which has no unpleasant smell or taste, making it easy to take.
8.8
Alleviated depression
Omega-3 has numerous benefits: it helps prevent heart diseases, improves brain function, enhances eyesight, boosts the immune system, and crucially, reduces feelings of depression and anxiety.
